Although rare, germline mutations in TP53 are associated with a significantly increased risk of female breast cancer, bone or soft tissue sarcomas, brain tumors and adrenocortical carcinomas (ACC) [3-7]. This evidence concerns the gene TP53 and soft tissue sarcoma.